Drugs / R-3,4-methylenedioxymethamphetamine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06905652 | Jul 2025 → May 2026 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT05277636 | Oct 2022 → Jan 2024 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R-3,4-methylenedioxymethamphetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277636 ↗ |
| Action | Inhibit | “The pharmacokinetic findings are consistent with the R-MDMA-mediated inhibition of CYP2D6.” PMID 39179638 ↗ Aug 2024 |
| Target | CYP2D6 | “The pharmacokinetic findings are consistent with the R-MDMA-mediated inhibition of CYP2D6.” PMID 39179638 ↗ Aug 2024 |